Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 81 85 EN Esra Cengiz Şanlıurfa Mehmet Akif İnan Education and Training Hospital, Şanlıurfa, Turkiye Muruvvet Aydin Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Ahmet Gunes Ankara Etlik City Hospital, Department of Hematology, Ankara, Turkiye Funda Ceran Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Simten Dagdas Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Gulsum Ozet Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye 2023 08 22 2024 02 04 Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms1. Therapies include chemotherapy or immunotherapy2-4 though stem cell transplantation (SCT) is the best consolidative approach in eligible patients5. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2075 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2075/1070